Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) took place on 27–29 June 2025, in Lisbon, Portugal. At this event, the world’s leading clinical researchers in MDS & MPNs shared their perspectives on how to place the evolving understanding of these hematological malignancies in a clinical context to optimize clinical care.
The iwMDS and MPN 2025 Workshop was supported by Agios, Faron, Genentech, Geron, Sumitomo Pharma, Bristol Myers Squibb, GSK and Kartos Therapeutics. Supporters have no influence over the production of content.
iwMDS 2025
The 3rd International Workshop on MDS & MPNs
27–29 June 2025 | Lisbon, Portugal
The 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) took place on 27–29 June 2025, in Lisbon, Portugal. At this event, the world’s leading clinical researchers in MDS & MPNs shared their perspectives on how to place the evolving understanding of these hematological malignancies in a clinical context to optimize clinical care.
The iwMDS and MPN 2025 Workshop was supported by Agios, Faron, Genentech, Geron, Sumitomo Pharma, Bristol Myers Squibb, GSK and Kartos Therapeutics. Supporters have no influence over the production of content.
Roundtable Discussions & Interviews
View all videos
Classification and risk stratification
Translational advances
Defining response criteria
TP53-mutated MDS
Novel pathways & therapeutic targets
iwMDS 2025: Lifetime achievement awards
Managing Lower-Risk MDS
Targeted & Immune Therapies in MDS
Controversies in transplant for MDS
Global Insights: MDS Trials & Real-World Data
Classification and risk stratification
Immunome in prognostication and immune interventions management in MDS
Shahram Kordasti King’s College London, London, United Kingdom
Molecular classification of MDS
Robert Hasserjian Massachusetts General Hospital, Boston, MA, United States
Roadmap for harmonization of classifications of myeloid malignancies: The icMDS recommendations
Luca Lanino Yale School of Medicine, CT, United States
Consistent trial design for MDS clinical trials – the icMDS recommendations
Uma Borate Ohio State University, Columbus, OH, United States
AI in classification and risk stratification of MDS
Adrián Mosquera Orgueira University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
Translational advances
Genetic characterization of therapy-relayed myeloid malignancies
Francesco Sole Josep Carreras Leukaemia Research Institute, Barcelona, Spain
Cardiovascular health in MPN patients
Defining response criteria in MDS
Should MRD be an endpoint in the assessment of MDS?
Arjan van de Loosdrecht Amsterdam UMC, Amsterdam, Netherlands
Should CR be achieved before alloBMT for HR-MDS?
Maximilian Stahl Yale Cancer Center, New Haven, CT, United States
From complexity to clarity: Defining clinical and regulatory frameworks for serial genetic testing in MDS
Coleman Lindsley Dana-Farber Cancer Institute, Boston, MA, United States
TP53-mutated MDS
How should TP53-mutated MDS be classified?
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
TP53-mutated MDS targeting – New directions
Thomas Cluzeau Central University Hospital of Nice, France
Novel insights on TP53-mutated MDS: An icMDS VALIDATE analysis
Tariq Kewan Yale School of Medicine, New Haven, CT, United States
Novel pathways and therapeutic targets in MDS
Updates on the biology of telomerase inhibition in MDS
Valeria Santini University of Florence, Florence, Italy
Is there a pathway forward for RARA agonists in MDS?
Amy DeZern Thomas Jefferson University, Baltimore, MD, United States
Updates on TGF pathway modulation in MDS
Hetty Carraway Cleveland Clinic, Cleveland, OH, United States
iwMDS 2025: Lifetime achievement awards
An incredible mentor
Ghulam Mufti King's College Hospital, London, United Kingdom
Evolving strategies in the management of lower-risk MDS
Keynote - Updates on QoL and PRO assessment in MDS: the icMDS recommendations
Fabio Efficace Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, IL, Italy
What do we know about luspatercept + ESA combinations for LR-MDS?
Lionel Ades Saint-Louis Hospital, Paris, France
How do I sequence imetelstat in MDS?
Mikkael Sekeres Sylvester Comprehensive Cancer Center, Miami, FL, United States
Advancements in targeted therapies and immunomodulation in MDS
An update on response assessment in MDS/AML
Lisa Pleyer Paracelsus Medical University, Salzberg, Austria
IRAK inhibitors in MDS – What’s next?
Anne Sophie Kubasch University of Leipzig, Leipzig, Germany
Controversies in transplant for MDS
Outcome for patients with MDS/MPN undergoing allogeneic stem cell transplantation: An analysis of >300 patients across 12 German centers
Katharina Götze Technical University of Munich, Munich, Germany
Recommendations for transplant for MDS in 2025
Carmelo Gurnari Cleveland Clinic, Cleveland, OH, United States
TP53 HR-MDS – Should you transplant or not?
Coleman Lindsley Dana-Farber Cancer Institute, Boston, MA, United States
Current situation of allogeneic transplantation for MDS in Japan
Yasushi Miyazaki Atomic Bomb Disease Institute, Nagasaki, Japan
Global perspectives on MDS trials – Clinical trials and real-world evidence
MDS trials in China
Bing Li Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
MDS trials in France
Lionel Ades Saint-Louis Hospital, Paris, France
MDS research in Greece
Ioannis Kotsianidis Thrace University, School of Medicine, Alexandroupolis, Greece
MDS trials in Spain
Adrián Mosquera Orgueira University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
